Treatment Action Group (TAG) applauds the legal actions undertaken by our colleagues from the Delhi Network of Positive People (DNP+) and tuberculosis (TB) survivor and activist Ganesh Acharya of Mumbai, with support from the Third World Network (TWN), contesting two patent applications on combinations of two decades-old TB medicines filed in India by French pharmaceutical company Sanofi.
The high cost of GeneXpert tests for tuberculosis (TB) leaves open a critical gap in the diagnosis of TB and fails to consider volume of sales and public investments in the development of GeneXpert.
October 31, 2019 — Civil society and community-based organizations issued this letter welcoming the availability of lower-priced rifapentine, which is an essential medicine for preventing TB. However, while all the organizations agree that this discount is a step forward, they're…
Presented at the 50th Union World Conference on Lung Health, an analysis by Treatment Action Group (TAG) finds that total public expenditures on the development of bedaquiline –– an important medicine for drug-resistant tuberculosis (DR-TB) –– far exceed those of the originator company, Johnson & Johnson.
Civil society and community-based organizations issued this statement welcoming the availability of lower-priced rifapentine, which is an essential medicine for preventing TB.
Letter from Organizations and Individuals to Cepheid asking them to reduce the price of Xpert MTB/RIF and Xpert MTB/RIF Ultra cartridges to US $5, inclusive of service and maintenance.
Access to quality diagnosis, treatment, and prevention for tuberculosis (TB) is a human right. Are the necessary tests, treatments, vaccines, services and policies available where you live or work? This new checklist from Treatment Action Group (TAG) lays out simply…
TAG's TB Activist Toolkits provide fundamental information about tuberculosis (TB) in order to strengthen global advocacy and understanding of the latest innovations, evidence, and guidance around TB and TB/HIV. These toolkits cover important base knowledge on TB and TB/HIV, as well…
In our two briefs, Closing the Gap in Tuberculosis Research and Development Funding: Actions for U.S. Government Executive Agencies and Actions for U.S. Congress, we detail how a funding increase of 0.1 percent, based on "fair share" of research capacity, would close the funding gap in TB R&D, catalyze new public health tools we need to create positive health outcomes among communities vulnerable to TB worldwide.
On January 11, 2019, TB Project Co-Director Lindsay McKenna attended a half-day conference hosted by the NYC Bureau of Tuberculosis Control. The recommendations from the conference are included in the NYC Department of Health and Mental Hygiene’s press release on the event, which you can download below.